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Abstract
Background: Many laboratories are reporting a numerical cut-
off index value (COI) value for most anti-SARS-CoV-2 qualita-
tive tests. These numerical values in patients’ report ultimately
created great confusion in the public and physicians, therefore this
study was designed to evaluate the correlation of electrochemilu-
minescence (ECLIA) based numerical COI values with quantita-
tive ELISA of anti-SARS-CoV-2 antibody. 
Design and Methods: Two hundred and twenty-eight (228)
recovered COVID-19 patients were included; their serum samples
were analyzed by quantitative ELISA and ECLIA for anti-SARS-
COV-2 antibodies. 
Results: One hundred and seventy-three (75.8%) patients test-
ed positive by ECLIA and ELISA assay and thirty-seven (6.2%)
were tested negative by both methods. A weak positive correlation
(r=0.37) was found between numerical COI value of ECLIA with
ELISA concentration, which was statistically significant with
p<0.001. All values were dispersed on scatter plot and there was
no significant linear relationship between ECLIA and ELISA
assay.
Conclusions: As both testing techniques are base upon the
same immunological phenomena of detecting antibodies against
nucleocapsid protein. We suggest that COI values are not meant to
describe the immunity level of the individuals thus the physicians
should not consider it as a quantitative value for antibody levels in
COVID-19 patients.
Introduction
On March 11, 2020 the World Health Organization (WHO)
declared COVID-19 a global pandemic.1 The causative agent of
COVID-19 is a corona virus named as SARS-CoV-2 and it belongs
to a family of viruses that may cause respiratory symptoms ranging
from common cold to severe pneumonia. The host or infected indi-
vidual in response to the infection produces specific antibodies
including IgM, IgG and IgA.2,3 The detection of these antibodies
indicates that the individual has been exposed to the virus. During
the recent pandemic, several diagnostics companies introduced test-
ing kits for detection of these antibodies, to estimate the percentage
of the population previously infected with the virus information
needed to devise strategies for community surveillance in order to
protect the public’s health.4 Many tests based on different techniques
are readily available in the market to detect the antibody. The two
most commonly used techniques to detect antibodies against SARS-
CoV-2 that entered the market included Electrochemiluminescence
Immunoassay (ECLIA) and Enzyme-linked Immunosorbent assay
(ELISA). ECLIA is a qualitative assay used to find the patients who
had been exposed to the virus while utilizing cut off index (COI) as
a reference to give a positive or negative result. The test targets anti-
bodies including IgG, IgM and IgA against nucleocapsid of SARS-
CoV-2. On the other hand, ELISA is a quantitative test intended to
define the titers of IgG in patients who had been previously
exposed.5 In case of SARS-CoV-2, it is still unknown if the presence
of IgG confers any protection against re-infection. As the number of
COVID cases increased, there was emergence of different tech-
niques to estimate the exposure of the population to the causative
agent and to detect the development of corresponding antibodies.
New techniques were developed and marketed to diagnose the dis-
ease in acute phase as well as to show the percentage of the popula-
tion that had been exposed to the virus.6 On the other hand, there
were techniques which were intended to show the quantitative values
of one specific types of antibody. Of these testing systems, ECLIA
based testing system and ELISA based Testing system have been
used by many laboratories in Pakistan.7
Both testing systems have been claimed to have high sensitiv-
ity and specificity,8 but COI is mistakenly considered as a quanti-
tative variable to define the overall anti- SARS-CoV-2 antibodies
in recovered patients. The objective of the current study was to
record any possible correlation of ECLIA based numerical COI
values provided by Roche Diagnostics (Rotkreuz, Switzerland).
testing system with quantitative ELISA provided by AEKULISA®
(AESKU Diagnostics; Wendelsheim, Germany) for anti- SARS-
CoV-2 antibody detection.
Significance for public health
Many laboratories in Pakistan are reporting numerical COI values, which ultimately created great confusion among the patients and physicians. These values are,
used indiscriminately and wrongly compared to other testing systems which were in general intended to be used for quantitative analysis of the antibodies developed
in the persons exposed to the virus. There had been obvious misunderstanding in the public including the healthcare sector when these different techniques were
used indiscriminately without a proper orientation towards the utility and limitations of a given testing system. As a result, the different numerical COI values
which were included in the laboratory reports of the test created a great havoc and raised suspicions about the certainty of the diagnostic techniques. This corre-












This prospective study was performed from 5th June to 30th
October 2020 at National Institute of Blood Disease and Bone
Marrow Transplantation (NIBD) Hospital, Karachi, Pakistan. The
adult fully recovered corona survivors of either gender aged 18 to
60 years were recruited after two weeks of negative PCR. All sub-
jects were healthy with no known co-morbidities. The study was
approved by institution’s ethical review committee. Three to five
ml blood sample was taken in EDTA tube for anti-SARS-CoV-2
antibody analysis by both ELISA and ECLIA. For quantitative
ELISA AESKULISA® SARS-CoV-2 NP IgG (AESKU
Diagnostics) was used the results were interpreted as positive at
cutoff >12U/ml, while <12 U/ml, were labeled as negative. Total
antibody IgG, IgM and IgA done by ECLIA on Cobas e-411
Immunoassay analyzer by Roche Diagnostics Cutoff index ≥1.0
used to label as reactive, while ≤1.0 used to label as non-reactive
as per manufacturer recommendations.
Statistical analysis 
Data was analyzed by EP evaluator (vers. 10.0). Mean and
Standard deviation for quantitative variables were calculated along
with frequencies for all categorical variables.  The mean values for
ECLIA anti-SARS-CoV-2 were calculated by using numerical cut
of index (COI) value. Scatter plots was created by using test
method as ECLIA on Y-axis and reference method as ELISA on X-
axis to see the relationship between COI and concentration.
Correlation coefficient (r value) was calculated by Pearson corre-
lation. Cohen’s Kappa was calculated to see the agreement,
Cohen’s Kappa >75% considered as high agreement. Furthermore,
t-test was applied to compare the means of ECLIA and ELISA and
p value of less than 0.05 was taken as statistically significant. 
Results
Two hundred and twenty-eight (228) COVID-19 survivors
were included in the study. The mean age of subjects was
36.6±11.6 years. There were 192 (84.2%) males and 62 (15.8%)
females. The mean anti-SARS-CoV-2 antibody by ECLIA was
30.38±31.04COI and by ELISA was 44.35±38.49U/ml. The mean
anti-SARS-CoV-2 antibody level was higher by ELISA and there
was a significant statistical difference between these two means
with p value <0.000. Approximately, 75.8% (173) individuals test-
ed positive either by ECLIA and ELISA or both whereas 16.2%
(37) tested negative by both methods. About 8.34% (18) individu-
als tested positive by ECLIA and tested negative by ELISA assay.
Antibody results obtained by ECLIA and ELISA of all patients
were used to create scatter plot, which gives slope of 0.69 (95% CI
- 0.60-0.78), intercept of -0.53 (95% CI - 5.83-4.78) and did not
show any significant linear relationship between ECLIA and
ELISA. Initial values we found a slightly uphill with a positive
slope but as we move forward, the data values were dispersed as
seen in Figure 1. There was very little positive relationship found
between the numerical COI value of ECLIA with quantitative
ELISA for anti-SARS-CoV-2 antibody with correlation coefficient
r=0.37 with p value <0.001.
Discussion
The current study was inspired by the curiosity to understand
the numerical COI values given by any ECLIA testing system to
address the confusion existent in the public and physicians that
whether higher COI values meant a higher humoral immunity level
(Ig level) or not. Although manufacturer of ECLIA had clearly
described the qualitative nature of the testing system, but the
included numerical values or COI reporting by laboratories were
creating confusion. Physicians were confused as well and were
considering these COI values comparable to Ig levels reported by
quantitative ELISAs. Every participant of the study was tested by
two antibody-based testing systems i.e. Eclesys® Roche testing
system using ECLIA technique and Quantitative ELISA by
AESKULISA® diagnostics testing system. We found lack of any
significant quantitative correlation between these two. The results
suggest that the COI values are not meant to describe the immunity
level of the individuals. The correlation of electrochemilumines-
cence based numerical COI of anti-SARS-CoV-2 antibody with
actual concentration is not reported in literature.
Many laboratories in Pakistan are reporting numerical COI
values, which ultimately created great confusion among the
patients and physicians. These values are, used indiscriminately
and wrongly compared to other testing systems which were in gen-
eral intended to be used for quantitative analysis of the antibodies
developed in the persons exposed to the virus. 
Stites et al. in 2020 determined IgG levels by using ELISA
technique as the serum was collected after 28 days of infection,
they did not perform IgM levels on ELISA as they collected sam-
ples after 4 weeks of illness and its already known that IgM levels
markedly reduced after 4weeks of infection.9 The positivity rate of
IgM antibody was only 60%, with a marked reduction in antibody
levels 4 weeks after onset of illness.10 Anti-SARS-CoV-2 S-specif-
ic IgG antibodies were identifiable from day 7 onwards, peaking at
approximately day 25 Serum IgG antibodies were still maintained
at a high level after 4 weeks of infection.11 Hou et al also reported
IgM levels increased during the first week after SARS CoV 2
infection, peaked 2 weeks and then reduced to near background
levels in most patients.12 There were 8.34% individuals who were
tested positive only by ECLIA system and negative by ELISA
based system, which may be due to IgM detected by Roche and not
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Figure 1. Scatter plot of ECLIA and ELISA assay showing weak









detected by ELISA although this could not be proven because of
the combo nature of the Roche ECLIA testing technique. We
strongly suggested that ECLIA being a qualititative test should be
reported as positive or negative. No numerical values for qualita-
tive assays should be documented in lab reports to avoid confusion
in physicians as well as nonclinical individuals. This suggestion is
in line with the manufacturer’s claim whose intention was to give
only the qualitative results, but confusion was created because of
the associated numerical values. As these COI values lack any rela-
tionship to the antibody/immunity status of an individual. This
practice has been adopted by our laboratory although some other
laboratories in our country are still issuing reports with numerical
values included thus creating confusion patients and physicians.
Conclusions
The results of this study suggest a lack of significant quantita-
tive correlation between these two testing systems.  Although
greater sample size may be required to find any possible correla-
tion, but it can be strongly suggested comparing these two systems.
Additionally studies are required to explain the meaning of numer-
ical values generated by the Roche system and their correlation
with the immunity status/antibody titers in a given individual.
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